Ruth O’Regan, MD, and Ann H. Partridge, MD, on HER2+ Breast Cancer: Results From the CLEOPATRA Trial
2016 San Antonio Breast Cancer SymposiumRuth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings on the prognostic associations of TILs in metastatic HER2-positive breast cancer (Abstract S1-04).
Related Videos
Eric P. Winer, MD: The McGuire Lecture
Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.
Diana M. Eccles, MD, on Young Breast Cancer Patients: Results From the POSH Study
Diana M. Eccles, MD, of the University of Southampton, discusses findings from a study of sporadic and hereditary breast cancer and whether BRCA status affects outcome in you...
Mothaffar Rimawi, MD, on HR-Positive, HER2-Positive Breast Cancer: Results of the NRG Oncology/NSABP B-52 Trial
Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-po...
Peter Bach, MD, on The Global Cost of Cancer Care
Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture...
Virginia G. Kaklamani, MD, DSc, on Early Breast Cancer: Year in Review
Virginia G. Kaklamani, MD, DSc, of The University of Texas Health Science Center, discusses new directions in prevention, early detection, and treatment of early-stage breast cancer, ...
